



# Unique genes: the innate immune response and tuberculosis



Tuberculosis (TB), caused by members of the *Mycobacterium tuberculosis* (*Mtb*), is a severe chronic disease that can affect humans and animals. *Mtb* is a leading cause of death in the world (1.5 million deaths every year). Among people who are infected, only 10% will develop TB, 90% of these infections are latent (LTBI). This pathology presents the difference in immune control of *Mtb*. Macrophages (M $\Phi$ s) are significant phagocytes that play a key role in [innate](#) and adaptive immunity. Their phenotypes stimulated with IFN $\gamma$  (pro-inflammatory) or IL-4, IL-13, and IL-10 (anti-inflammatory) determine the type of *Mtb* response.

In a recent paper, Khan, et al., hypothesized that the M $\Phi$  phenotype can enhance anti-TB function following cytokine stimulation, and this stimulation can explain the development of LTBI (Figure 1). They showed that infected M1-M $\Phi$ s survived better with upregulation of genes and pathways that regulate antigen processing Compared to M2-M $\Phi$ s. They highlight also M1-M $\Phi$ s driven with IFN- $\gamma$  increased the ability to bacterial control with the pro-inflammatory cytokine, nitric oxide expression, and autophagy-dependent degradation of *Mtb*, whereas IL-4 programmed M2-polarized M $\Phi$ s (M2-M $\Phi$ s) are permissive for *Mtb* proliferation.



**Figure 1: Human umbilical cord and peripheral blood-derived macrophages show heterogeneity in mycobacterial killing associated with oxidants and autophagy.** Human cord blood (CBM) or healthy donor PBMC-derived M $\phi$ s were cultured in the presence of either recombinant human IFN- $\gamma$  (M1; 10 ng/mL) or human IL-4 (M2; 10 ng/mL) for 5 days and rested for 2 days. Untreated cells were M0-M $\phi$ s. **a, b** Surface expression of receptors by CBM-derived naïve and *Mycobacterium tuberculosis* (Mtb; H37Rv)-infected M1- (CD80+/CD206-) and M2-M $\phi$ s (CD80-/CD206+) on day 3 using flow cytometry and quantitation (\* $p < 0.01$  t test); gating strategy shown Supplemental Fig. 1. **c** CBM-derived differentiated M $\phi$ s were

*infected with Mtb for 4 h followed by microscopic counts of rfp-labeled MtbH37Rv to determine uptake verified using CFU counts. d PBMC-derived MΦs from five healthy donors were differentiated using the indicated cytokines followed by infection with Mtb and CFU assay on day 4. Each point represents one donor (\*\*p < 0.05; Kruskal–Wallis test). e PBMC-derived MΦs were differentiated using GM-CSF (M1), IL-4 (M2a), IL-1β (M2b), IL-10 (M2c) or left untreated (M0) followed by Mtb infection and CFU assay on day 4 (\*\*p < 0.007). f CBM-derived, cytokine differentiated MΦs were infected with Mtb followed by CFU assay over time (\*\*p < 0.006; data from 3 experiments shown). g CBM-derived, differentiated MΦs were infected with M. bovis BCG followed by CFU assay on day 4 (\*\*p < 0.005). h CBM-derived and differentiated uninfected MΦs or those infected with Mtb or BCG were incubated and at indicated time points, cultures were tested for nitrite using diaminofluorescein diacetate and fluorometry (\*, \*\*p < 0.005, t test). QPCR for mRNA of iNOS and protein are shown in*

Supplemental Fig. 3a and reactive oxygen species levels in Supplementary Fig. 3b. i MΦs infected with Mtb as in panel h were incubated in NMMA (0.5 mM; N-monomethyl L-arginine) followed by CFU assay on day 3 (\*\*p < 0.009). j CBM-derived, differentiated MΦs infected with Mtb were incubated with 10 μM Rapamycin, 100 μM Metformin or their combination followed by CFU assay on day 3 (\*\*p < 0.009). k CBM-derived, M1-, M2- and M0-MΦs were treated in the presence or absence of siRNA vs. beclin1 (ATG6) or its scrambled control followed by infection with Mtb and CFU counts on day 3 (\*p < 0.007). Blot validation of Knockout using siRNA vs. beclin1 (ATG6) is shown in Fig. 3h. l MΦ lysates of panel k collected at 18 h were analyzed using western blots for the lipidation of microtubule-associated light chain 3 (LC3). Lipidation is indicated by LC3-II. m CBM-derived MΦs were infected with rfpMtbH37Rv and stained for an LC3 autophagy marker or LAMP1 lysosome marker using specific antibodies, Alex-Fluor485 conjugates, and imaged using confocal microscopy. Panels illustrate

*LC3 colocalization; LAMP1 stains using gfpMtbH37Rv is shown in Supplementary Fig. 3c. n Quantification of phagosomes colocalizing with LC3 are shown using an N90 Nikon fluorescence microscope (IF) and Metaview software (\*p < 0.004, t test). For panels (b-c-e-f-g-h-i-b-k-n), p-values were calculated using a one-way ANOVA with Tukey's post-hoc test; one of 2-3 similar experiments shown. CFU or IL-2 assays had triplicate wells plated per group or donor. Panels (d, g, i-k) horizontal dotted lines indicate day 0 CFU (4 h post-infection CFU). All Mtb CFU experiments used MOI of 1.*

They found that positive autophagy regulation in Mtb-infected M1-MΦs strongly expressed Sirtuin5, HDAC2 (positive autophagy regulator). However, the expression of Sirtuin2 (negative autophagic regulator) Mtb-infected M2-MΦs was correlated to bacterial survival. They finally suggested that M1 and M2 phenotypes can mediate anti-TB response in humans and macaques. The gene expression difference could be used as Host directed therapeutic targeting MΦs polarization.

**Journal article: Khan, A. et al., 2022. [Human M1 macrophages express unique innate immune response genes after mycobacterial infection to defend against tuberculosis.](#) *Communications biology.***

*Summary by Mberkadji Ngana*

